Fig. 15

a Fusacandin B contains three circular sugars, two terminal (in red) and one non-terminal (in blue), all linked to the neighbouring structure by a glycosidic bond (in purple). b 7-[(Acetyloxy)methyl]-4-({[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3-(4-hydroxyphenyl)prop-2-enoyl]oxy}oxan-2-yl]oxy}methyl)-6,7-dihydroxy-1H,4aH,5H,6H,7H,7aH-cyclopenta[c]pyran-1-yl 3-methylbutanoate with a non-terminal ring sugar (in red) linked by two glycosidic bonds (in purple) to the parental structures. c 5,6-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl 3,4,5,6-tetrahydroxyoxane-2-carboxylate contains one terminal circular sugar (in red) that is not linked to the parent structure by a glycosidic bond. d 2,10-Bis(hydroxymethyl)-1,6,9,13-tetraoxadispiro[4.2.4⁸.2⁵]tetradecane-3,4,11,12-tetrol contains a circular sugar moiety (in red) that has a spiro carbon in its structure to link it to the rest of the molecule. e 2,3-Hexahydroxydiphenoxyl-glucose molecule with a non-terminal sugar ring (in red) where the ratio of exocyclic oxygens is bigger than 1 and that is linked to the parental structures by glycosidic bonds (in purple). f Tobramycin with two terminal ring sugars, linked by glycosidic bonds (in purple); the sugar in red has a ratio of exocyclic oxygens to atoms in the sugar ring ≥ 0.5 and the one in blue < 0.5